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Abstract
Background: Evidence suggests that Oxidative stress has been shown to plays an
important role in gestational diabetes mellitus (GDM) etiology. On the other hand,
women with GDM are at an increased risk for complications such as endothelial
dysfunction and cardiovascular diseases.
Objective: To investigate the effects of alpha-lipoic acid (ALA) on the maternal
circulating values of lipid profile and lipid ratios in women with GDM.
Materials and Methods: Sixty women with GDM were participated in the present
study. The ALA group (n = 30) received ALA (100 mg/day) and the placebo group
(n = 30) received cellulose acetate (100 mg/day) for eight wk. The maternal circulating
values of hemoglobin A1C, triglyceride (TG), total cholesterol, high-density lipoprotein
cholesterol (HDL-C), low-density lipoprotein cholesterol, triglyceride-glucose (TyG)
index, atherogenic index of plasma (AIP), non-HDL-C, and lipid ratios were assessed
before and after the intervention. P-value < 0.05 was considered as statistically
significant.
Results: The values of TyG index (p < 0.001), TG (p = 0.006), TG/HDL-C (p = 0.003), and
AIP (p = 0.005) decreased significantly in the ALA group after the intervention.
Conclusion:Maternal circulating values of TyG index, TG, TG/HDL, AIP decreased after
eight wk of ALA supplementation in women with GDM.
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1. Introduction
Gestational diabetes mellitus (GDM) is a
condition that is initiated or diagnosed for the first
time in pregnancy, which is defined as glucose
intolerance. This type of diabetes increases insulin
resistance in body. Mothers suffering from GDM
are at a high risk for type 2 diabetes in future.
Clinical studies have shown that oxidative stress
plays a role in the pathophysiology of numerous
diseases (1). Normal pregnancy is regarded as
a condition associated with increased oxidative
stress. However, despite the increasing oxidative
stress, there is a balance between antioxidants
and oxidants in normal pregnancy. Bodies of
evidence suggest that oxidative stress plays
an important role in pregnancy complications
such as GDM, preeclampsia, and hydatidiform
mole (2, 3). Alpha-lipoic acid (ALA) (6, 8-thioctic
acid or 1,2-dithiolane-3-pentanoic acid) is a
sulfur-containing fatty acid (C8H14O2S2; MW
206.32) that plays a basic role as an antioxidant
and is required for mitochondrial α-ketoacid
dehydrogenase complex. ALA is produced by
plants and animals. However, its synthesis in
human is very low (4). Its antioxidant properties
are attributed to several reasons including its
capacity for direct scavenging of reactive oxygen
species (ROS), regeneration of endogenous
antioxidants such as glutathione, vitamins E
and C, and its metal-chelating activity (5).
Short-term treatment with ALA in patients
with type 2 diabetes mellitus (T2DM) has
been suggested to improve lipid profile by
improving oxidative stress and inflammatory
responses (6). A systematic review has shown
that supplementation with ALA can improve lipid
profile except HDL-C in patients with metabolic
diseases (7).
A review study has suggested that ALA
not only has no side effects but also has
protective effects against embryopathy, fetal
mortality, and placental ultrastructural changes
due to diabetes during pregnancy (8). Women
with a history of GDM are at an increased
risk for complications such as endothelial
dysfunction and cardiovascular diseases (9).
It has been shown that lipid profile controlling
during GDM can prevent impairment of the
feto-placental endothelial function (10). On
the other hand, women who use insulin
during GDM can face some cardiovascular
complications compared to those who undergo
nutritional therapy for controlling the disease
(11). However, little data are available about
the effects of ALA supplementation on the
values of lipid profile and lipid ratios in women
with GDM. Therefore, the current clinical trial
study was designed to investigate into this
matter.
2. Materials and Methods
2.1. Study registration and approval
The current clinical trial study was conducted
at the Taleghani Hospital and Diabetes Clinic
of Arak University of Medical Sciences between
February 2017 and January 2018. The study is a
double-blind clinical trial in which the participants
and the statistician were not aware of the type
of drug to be administered and the group
classification, respectively. GDM diagnosis was
carried out according to the 75-gr oral glucose
tolerance test when at least one or more of
the following glucose values were exceeded:
fasting ≥ 92 mg/dl; 1 h ≥ 180 mg/dL; and 2
h ≥ 153 mg/dL (12). The inclusion criteria of the
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study were: diagnosis of GDM, 18-40 yr of age,
and being resident. The exclusion criteria, on
the other hand, included: receiving antioxidant
supplements at six-month intervals before the
trial, preterm delivery, preeclampsia and other
complications during the intervention stage, liver
diseases, the need for insulin or medication during
the intervention stage, absolute rest, smoking, and
previous GDM history. Accordingly, 70 women,
who were diagnosed with GDM by a specialist
physician during 24 and 28 weeks of pregnancy,
were selected using the convenience sampling
method. Of them, 10 were excluded based on the
inclusion criteria. Thus, 60 of them were enrolled
in the current study (Figure 1).
2.2. Randomization
Participants were divided into ALA and placebo
groups using simple randomization method by
the random number table. While 30 participants
were included in the ALA group and received ALA
(Puritan’s Pride, Oakdale, NY, USA) (1 capsule 100
mg/day), the remaining 30 were included in the
placebo group and received manually prepared
capsule containing cellulose acetate (Sigma
Aldrich, St. Louis, USA) (1 capsule 100 mg/day).
The intervention lasted for eight weeks. Studies
have shown that a single dosage administration
(50-600 mg) of ALA is completely absorbed
within 30-60 min (8). Since receiving 100 mg/day
of ALA has been shown to have no significant
side effects on mothers and newborns during
pregnancy (8), this dosage was used in the
current study. All subjects were under the
same diet plan for controlling blood glucose
levels. Participants were asked to follow the
provided diet plan and not to change their
ordinary daily physical activity during the trial.
As a reminder, every two weeks, the patients
were phone called for taking their capsules
appropriately.
2.3. Assessment of variables
Demographic data including participants’
height, weight (light clothing without shoes
weight), body mass index (BMI), blood pressure
(right arm in sitting position) were measured
at the beginning and end of the trial. BMI was
determined as weight (kg)/height (m2). Venous
blood samples were taken after 12 hr of fasting at
the beginning and end of the intervention. Blood
samples were centrifuged at 10,000 g for 15
min. Serum samples were stored at -80°C before
analysis. To measure hemoglobin A1C (HbA1c), 1.5
ml of total blood was poured into EDTA-containing
tubes that were assayed by chromatography kit
(Biosystems, Barcelona, Spain).
Moreover, fasting blood sugar (FBS), high-
density lipoprotein cholesterol (HDL-C),
triglyceride (TG), and total cholesterol (TC)
(ZiestChem Diagnostic, Tehran, Iran) were
measured using a chemical analyzer (BT3500,
Italy). Low-density lipoprotein cholesterol (LDL-C)
levels were calculated using the Friedewald
equation (13). The atherogenic index of plasma
(AIP) (14), the triglyceride-glucose (TyG) index as
Ln [(FBS × TG)/2] (15), the non-HDL-C, and the lipid
ratios including TG/HDL-C, TC/HDL-C, LDL-C/HDL-
C, and TG/TC were calculated (16). Levels of
thiobarbituric acid-reactive substances (TBARS),
a measure of lipid peroxidation, were determined
for evaluating oxidative stress status (17). Serum
ALA levels were measured by high-performance
liquid chromatography method (KNAUER, Berlin,
Germany) (18).
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Figure 1. Consort diagram of ALA supplementation effects on lipid profile in women with gestational diabetes mellitus.
2.4. Ethical consideration
The current study was approval by the Ethics
Committee (IR.ARAKMU.REC.1395.343) of the
Taleghani Hospital and Diabetes Clinic of Arak
University of Medical Sciences.
2.5. Statistical analysis
Qualitative data were evaluated using the
Chi-square test. The normal distribution of
variables was explored by the Kolmogorov-
Smirnov test. Comparisons of quantitative
parameters were performed using paired and
independent t tests. Interactions between the
corresponding biochemical variables and the
ALA group were explored using the Analysis of
Covariance (ANCOVA). Data with p-values < 0.05
were considered as significant. All data are
expressed as mean ± SEM. All statistical
analyses were conducted using the SPSS,
version 21 for windows (SPSS Inc., Chicago, IL,
USA).
3. Results
In this study, data of the participants in
two groups (n = 30/each) were analyzed.
No significant differences were observed
in the demographic and biochemical data
of the two groups at the baseline (Tables I
and II). In addition, no significant changes
were observed in the weight, systolic blood
pressure, and BMI in each group following the
intervention.
Intragroup and intergroup comparisons of
the variables are given in Tables III and IV,
respectively. At the end of the intervention,
values of FBS (p < 0.001), TyG index (p < 0.001),
TG (p = 0.006), TG/HDL-C (p = 0.003), TG/TC
(p = 0.004), AIP (p = 0.005), and TBARS
(p < 0.001) significantly decreased in the ALA
group compared with the baseline. Values
of HbA1C decreased marginally in the ALA
group (p = 0.059). No significant changes were
observed in the values of TC (p = 0.189), LDL-
C (p = 0.104), HDL-C (p = 0.328), non-HDL-C
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(p = 0.750), LDL-C/HDL-C (p = 0.727), and TC/HDL-
C (p = 0.750) compared with the baseline in
the ALA group. A comparison between the
two groups showed a significant reduction in
the serum levels of FBS (p < 0.001), TyG index
(p = 0.022), TG (p = 0.041), TG/HDL-C (p = 0.016),
TG/TC (p = 0.036), and AIP (p = 0.034) in the
ALA group compared with the placebo group.
However, no significant changes were observed
in the values of HbA1C (p = 0.496), TC (p = 0.667),
LDL-C (p = 0.441), HDL-C (p = 0.354), non-HDL-
C (p = 0.978), LDL-C/HDL-C (p = 0.710), and
TC/HDL-C (p = 0.357) between the two groups
after the supplementation.
At the end of the trial, serum levels of ALA
were increased in the ALA group (1.10 ± 0.10 vs
4.51 ± 0.24 µg/ml, p < 0.001), while no changes
were observed in the placebo group (1.14 ± 0.07
vs 1.12 ± 0.07 µg/ml, p = 0.134).
Results of the ANCOVA test were significant
for the TyG index (p = 0.001), TG (p < 0.001),
TG/HDL-C (p = 0.006), AIP (p = 0.012), and TBARS
(p = 0.007). However, it was not significant for the
TG/TC (p = 0.308).
Table I. Baseline biochemical characteristics of women with gestational diabetes mellitus in ALA and placebo groups
Variables ALA (n = 30) Placebo (n = 30) P-value¥
TG (mg/dl) 250.69 ± 8.69 243.22 ± 9.01 0.553
TyG index 9.43 ± 0.04 9.38 ± 0.03 0.421
TC (mg/dl) 228.22 ± 3.99 234.70 ± 5.76 0.553
HDL-C (mg/dl) 43.99 ± 1.51 42.25 ± 1.04 0.347
Non-HDL-C (mg/dl) 184.23 ± 4.38 192.45 ± 5.87 0.266
LDL-C (mg/dl) 134.08 ± 4.64 143.80 ± 5.42 0.179
TG/HDL-C 5.86 ± 0.262 5.83 ± 0.238 0.938
TC/HDL-C 5.36 ± 0.213 5.66 ± 0.203 0.326
LDL-C/HDL-C 3.19 ± 0.189 3.49 ± 0.174 0.251
AIP 0.755 ± 0.02 0.756 ± 0.01 0.964
TG/TC 1.11 ± 0.04 1.04 ± 0.04 0.256
Note: Data are expressed as Mean ± SEM. ¥ Based on independent t test, TG: Triglyceride; TyG: Triglyceride-glucose; LDL-C:
Low-density lipoprotein cholesterol; AIP: Atherogenic index of plasma; TC: Total cholesterol; HDL-C: High-density lipoprotein
cholesterol
Table II. Baseline general characteristics of women with gestational diabetes mellitus in ALA and placebo groups
Variables ALA (n = 30) Placebo (n = 30) P-value
Age (yr)* 30.96 ± 0.93 31.10 ± 0.92 0.918¥
Height (cm)* 163.00 ± 0.97 162.10 ± 1.21 0.579 ¥
Gestational age (wk)* 26.28 ± 0.23 26.51 ± 0.24 0.472¥
Family history of diabetes** 13 (43.3%) 12 (40.0%) 0.999$
Weight (kg)* 70.70 ± 1.91 70.90 ± 2.04 0.942¥
BMI (kg/m2)* 26.64 ± 0.71 26.95 ± 0.73 0.793¥
SBP (mmHg)* 107.17 ± 2.49 108.00 ± 2.01 0.796¥
Note: * Data are expressed as Mean ± SEM. **Data presented as n (%),
¥Based on independent t test; $Based on Chi-square test
BMI: Body mass index; SBP: Systolic blood pressure
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Table III. Comparison of parameters within ALA and placebo groups before and after intervention in women with gestational
diabetes mellitus
ALA (n = 30) Placebo (n = 30)Variables
Before After P-value Before After P-value
HbA1C (%)* 5.29 ± 0.13 4.94 ± 0.13 0.059 5.31 ± 0.12 5.09 ± 0.16 0.274
FBS (mg/dl) * 101.43 ± 1.69 83.56 ± 1.31 <0.001‡ 100.00 ± 1.24 94.63 ± 1.18 0.001‡
TG (mg/dl) * 250.69 ± 8.69 221.15 ± 6.91 0.006‡ 243.22 ± 9.01 248.33 ± 11.01 0.611
TyG index* 9.43 ± 0.04 9.11 ± 0.04 <0.001‡ 9.38 ± 0.03 9.33 ± 0.05 0.339
TC (mg/dl) * 228.22 ± 3.99 235.51 ± 4.32 0.189 234.70 ± 5.76 232.80 ± 4.53 0.739
HDL-C (mg/dl) * 43.99 ± 1.51 46.48 ± 1.81 0.328 42.25 ± 1.04 43.95 ± 1.99 0.463
Non-HDL-C (mg/dl) * 184.23 ± 4.38 189.03 ± 4.62 0.750 192.45 ± 5.87 188.84 ± 4.99 0.752
LDL-C (mg/dl) * 134.08 ± 4.64 144.80 ± 4.81 0.104 143.80 ± 5.42 139.17 ± 5.41 0.503
TG/HDL-C* 5.86 ± 0.262 4.91 ± 0.193 0.003‡ 5.83 ± 0.238 5.87 ± 0.337 0.914
TC/HDL-C* 5.36 ± 0.213 5.27 ± 0.207 0.750 5.66 ± 0.203 5.57 ± 0.246 0.752
LDL-C/HDL-C* 3.19 ± 0.189 3.29 ± 0.184 0.727 3.49 ± 0.174 3.39 ± 0.215 0.703
AIP* 0.755 ± 0.02 0.680 ± 0.01 0.005‡ 0.756 ± 0.01 0.748 ± 0.02 0.755
TG/TC* 1.11 ± 0.04 0.95 ± 0.03 0.004‡ 1.04 ± 0.04 1.07 ± 0.05 0.567
Note: * Data are expressed as Mean ± SEM. ‡Significant at p < 0.05, based on paired t test
HbA1C: Hemoglobin A1C; FBS: Fasting blood sugar; TG: Triglyceride; TyG: Triglyceride-glucose; LDL-C: Low-density lipoprotein
cholesterol; AIP: Atherogenic index of plasma; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol
Table IV. Comparison of parameters between ALA and placebo groups before and after intervention in women with gestational
diabetes mellitus
ALA (n = 30) Placebo (n = 30) PvalueVariables
Before After Before After Before After
HbA1C (%)* 5.29 ± 0.13 4.94 ± 0.13 5.31 ± 0.12 5.09 ± 0.16 0.913 0.496
FBS (mg/dl) * 101.43 ± 1.69 83.56 ± 1.31 100.00 ± 1.24 94.63 ± 1.18 0.497 <0.001¥
TG (mg/dl) * 250.69 ± 8.69 221.15 ± 6.91 243.22 ± 9.01 248.33 ± 11.01 0.553 0.041¥
TyG index* 9.43 ± 0.04 9.11 ± 0.04 9.38 ± 0.03 9.33 ± 0.05 0.421 0.002¥
TC (mg/dl) * 228.22 ± 3.99 235.51 ± 4.32 234.70 ± 5.76 232.80 ± 4.53 0.553 0.667
HDL-C (mg/dl) * 43.99 ± 1.51 46.48 ± 1.81 42.25 ± 1.04 43.95 ± 1.99 0.347 0.354
Non-HDL-C (mg/dl) * 184.23 ± 4.38 189.03 ± 4.62 192.45 ± 5.87 188.84 ± 4.99 0.266 0.978
LDL-C (mg/dl) * 134.08 ± 4.64 144.80 ± 4.81 143.80 ± 5.42 139.17 ± 5.41 0.179 0.441
TG/HDL-C* 5.86 ± 0.262 4.91 ± 0.193 5.83 ± 0.238 5.87 ± 0.337 0.938 0.016¥
TC/HDL-C* 5.36 ± 0.213 5.27 ± 0.207 5.66 ± 0.203 5.57 ± 0.246 0.326 0.357
LDL-C/HDL-C* 3.19 ± 0.189 3.29 ± 0.184 3.49 ± 0.174 3.39 ± 0.215 0.251 0.710
AIP* 0.755 ± 0.02 0.680 ± 0.01 0.756 ± 0.01 0.748 ± 0.02 0.964 0.034¥
TG/TC* 1.11 ± 0.04 0.95 ± 0.03 1.04 ± 0.04 1.07 ± 0.05 0.256 0.036¥
weight (kg) * 70.70 ± 1.91 73.08 ± 1.79 70.90 ± 2.04 73.57 ± 2.13 0.943 0.863
Weight change (kg) * 2.38 ± 0.38 2.67 ± 0.55 0.676
Note: *Data are expressed asMean± SEM. ¥ Significant at p< 0.05, based on independent t test. HbA1C: Hemoglobin A1C; FBS:
Fasting blood sugar; TG: Triglyceride; TyG: Triglyceride-glucose; LDL-C: Low-density lipoprotein cholesterol; AIP: Atherogenic
index of plasma; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol
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4. Discussion
The current study showed that the maternal
circulating values of TyG index, TG, TG/HDL-
C, and AIP decreased after an eight-week
supplementation with ALA in womenwith GDM.
ALA supplementation at a dosage of 100 mg/day
in women with GDM showed no significant
changes in weight, systolic blood pressure, and
BMI in both groups.
De Cicco and colleagues (19) found that
the combination therapy with ALA and myo-
inositol significantly reduces BMI in women with
polycystic ovary syndrome. Noori and colleagues
(20) found that consumption of 800 mg of ALA
in diabetic nephropathy significantly decreases
systolic blood pressure in the supplement group
compared with the placebo group.
Orally consumed ALA is absorbed almost
entirely from intestine (21). In the current study,
values of ALA increased significantly in the
treatment group compared with the placebo
group after the intervention. Therefore, this finding
can be accounted for ALA consumption by
participants in the ALA group.
In addition, in the current study, HbA1C levels
decreased marginally in the ALA group after
supplementation with ALA, albeit the absence of
statistical significance according to the results of
ANCOVA. Accordingly, marginally reduced values
of HbA1C may not be attributed to the intervention
effects. Bao and co-workers (22) found that
the daily consumption of 600 mg of ALA in
patients with T2DM does not change HbA1C
levels significantly. Chang and co-workers (23)
observed that using 600 mg of ALA for 12 weeks
does not affect HbA1c levels in individuals with
end-stage renal disease. Porasuphatana and co-
workers (24) observed that taking different doses
of 300, 600, 900, and 1200 mg/day of ALA for
six months causes a significant reduction in the
HbA1C levels in individuals with T2DM. Derosa
and co-workers (5) found that taking 600 mg of
ALA supplementation in individuals with T2DM
reduces HbA1C levels significantly.
An in vitro study conducted by Di Fulvio and
co-workers (9) has shown that vascular cells
obtained from umbilical cords of womenwith GDM
maintain certain dysfunctions such as increased
ROS and reduced nitric oxide (NO) bioavailability
even after culturing for several times. Another in
vitro study conducted by Di Tomo and colleagues
(25) has shown that ALA significantly improves
detrimental effects of hyperglycemia on umbilical
vein endothelial cells obtained from mothers
with GDM, concluding that this may point to
new strategies for prevention of diabetes-related
vascular complications.
A systematic review study has shown that
supplementation with ALA can improve lipid
profile except HDL-C in individuals with metabolic
diseases (7). However, little data are available
in this matter in GDM. In the current study, the
mean TC/HDL and LDL/HDL level changes in
the ALA and placebo groups did not show a
statistically significant difference. However, the
mean TyG index, TG, TG/TC, TG/HDL, and AIP
levels in the ALA group significantly decreased
after the intervention. It has been reported that
the increased values of TyG index, TG, and
TG/HDL-C in early pregnancy are associated
with high incidence of GDM development (15).
The TyG index is the best indicator of insulin
resistance compared with other lipid parameters
as a noninvasive, effective, and simple tool. On
the other hand, TyG index is a better predictor
of atherosclerosis than homeostatic model
assessment of insulin resistance (HOMA-IR)
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(15, 26). AIP value has been shown to be a
good biomarker for the risk of atherosclerosis
and cardiovascular diseases. In addition, the
calculation of AIP, especially when lipid profile
is in normal range, has been proposed, which
can show more useful data than traditional lipid
analysis about patient’s situation (14, 27). Results
from the ANCOVA did not point to a statistically
significant difference for TG/TC. Therefore,
reduced TG/TC valuesmay not be attributed to the
intervention effects. An increase in the TG/HDL-C
ratio was reported in GDM compared with healthy
pregnancy (28). The TC/HDL-C, LDL-C/HDL-C,
and TG/HDL ratios showed significant positive
correlations with HOMA-IR. Therefore, these ratios
could be used as simple alternative markers for
assessing insulin resistance during pregnancy
and predicting women at a high risk for GDM
(29). It has been shown that ALA can increase
adenosine monophosphate-activated protein
kinase (AMPK) activity which causes inhibition of
fatty acid synthesis, while simultaneously fatty
acids oxidation is activated. On the other hand,
expression of enzymes acetyl-CoA carboxylase
and fatty acid synthase, two rate-limiting enzymes
in fatty acid synthesis, are depressed in subjects
supplemented with ALA (7).
A major limitation of the present study was
the lack of a healthy control group to allow
the comparison of the results obtained from the
participants with them.
5. Conclusion
The results of the current study in women
with GDM showed a significant decrease in the
maternal circulating values of TyG index, TG,
TG/HDL, AIP, and TBARS in the ALA group
compared to the placebo group at the end of the
intervention. More studies are required to evaluate
the potential effects of ALA on the reduction of
birth defects in women suffering from GDM.
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